重组人生长激素对矮小症患儿血清IGF-1及骨龄的影响

Influence of Recombinant Human Growth Hormone on Serum IGF-1 and Bone Age in Children with Dwarfism

目的探讨重组人生长激素(rhGH)对矮小症患儿血清胰岛素样生长因子-1(IGF-1)及骨龄的影响。方法选择2019年8月至2021年7月我院收治的81例矮小症患儿,依据治疗方法不同分为研究组(41例)及对照组(40例)。对照组采用常规营养治疗,研究组在对照组基础上采用rhGH治疗。两组均连续治疗1年。对比两组的血清学指标[25(OH)D、IGF-1]及生长情况。结果治疗后,研究组的25(OH)D、IGF-1水平及身高、体重、骨龄均高于对照组(P<0.05)。两组的并发症发生率比较,差异无统计学意义(P>0.05)。结论rhGH治疗矮小症患儿能够有效提高血清IGF-1水平,促进生长发育,安全性高,值得临床推广。

Objective To explore the influence of recombinant human growth hormone(rhGH)on serum insulin-like growth factor-1(IGF-1)and bone age in children with dwarfism.Methods 81 children with dwarfism admitted to our hospital from August 2019 to July 2021 were selected and divided into study group(41 cases)and control group(40 cases)according to different treatment methods.The control group received routine nutrition treatment,while the study group was treated with rhGH on the basis of the control group.Both groups were treated continuously for 1 year.The serological indicators[25(OH)D,IGF-1]and the growth of the two groups were compared.Results After treatment,the 25(OH)D and IGF-1 levels,and the height,weight and bone age of the study group were higher than those of the control group(P<0.05).No statistical difference was found in the incidence of complications between the two groups(P>0.05).Conclusions rhGH in the treatment of children with dwarfism can effectively improve the serum IGF-1 level,promote the growth and development,with high safety,which is worthy of clinical promotion.